S&P 500   4,171.78 (-0.80%)
DOW   32,783.07 (-0.79%)
QQQ   347.46 (-0.72%)
AAPL   178.87 (+0.89%)
MSFT   329.30 (-0.58%)
META   262.44 (-0.03%)
GOOGL   123.30 (-0.30%)
AMZN   119.53 (-1.75%)
TSLA   196.44 (-2.35%)
NVDA   386.32 (-3.69%)
NIO   7.26 (-2.02%)
BABA   78.15 (-0.66%)
AMD   119.66 (-4.48%)
T   15.82 (+1.15%)
F   12.02 (-4.53%)
MU   67.98 (-5.18%)
CGC   0.81 (-5.10%)
GE   100.00 (-2.34%)
DIS   87.27 (-0.63%)
AMC   4.43 (-4.32%)
PFE   37.61 (+1.62%)
PYPL   61.47 (-0.93%)
NFLX   393.26 (+0.07%)
S&P 500   4,171.78 (-0.80%)
DOW   32,783.07 (-0.79%)
QQQ   347.46 (-0.72%)
AAPL   178.87 (+0.89%)
MSFT   329.30 (-0.58%)
META   262.44 (-0.03%)
GOOGL   123.30 (-0.30%)
AMZN   119.53 (-1.75%)
TSLA   196.44 (-2.35%)
NVDA   386.32 (-3.69%)
NIO   7.26 (-2.02%)
BABA   78.15 (-0.66%)
AMD   119.66 (-4.48%)
T   15.82 (+1.15%)
F   12.02 (-4.53%)
MU   67.98 (-5.18%)
CGC   0.81 (-5.10%)
GE   100.00 (-2.34%)
DIS   87.27 (-0.63%)
AMC   4.43 (-4.32%)
PFE   37.61 (+1.62%)
PYPL   61.47 (-0.93%)
NFLX   393.26 (+0.07%)
S&P 500   4,171.78 (-0.80%)
DOW   32,783.07 (-0.79%)
QQQ   347.46 (-0.72%)
AAPL   178.87 (+0.89%)
MSFT   329.30 (-0.58%)
META   262.44 (-0.03%)
GOOGL   123.30 (-0.30%)
AMZN   119.53 (-1.75%)
TSLA   196.44 (-2.35%)
NVDA   386.32 (-3.69%)
NIO   7.26 (-2.02%)
BABA   78.15 (-0.66%)
AMD   119.66 (-4.48%)
T   15.82 (+1.15%)
F   12.02 (-4.53%)
MU   67.98 (-5.18%)
CGC   0.81 (-5.10%)
GE   100.00 (-2.34%)
DIS   87.27 (-0.63%)
AMC   4.43 (-4.32%)
PFE   37.61 (+1.62%)
PYPL   61.47 (-0.93%)
NFLX   393.26 (+0.07%)
S&P 500   4,171.78 (-0.80%)
DOW   32,783.07 (-0.79%)
QQQ   347.46 (-0.72%)
AAPL   178.87 (+0.89%)
MSFT   329.30 (-0.58%)
META   262.44 (-0.03%)
GOOGL   123.30 (-0.30%)
AMZN   119.53 (-1.75%)
TSLA   196.44 (-2.35%)
NVDA   386.32 (-3.69%)
NIO   7.26 (-2.02%)
BABA   78.15 (-0.66%)
AMD   119.66 (-4.48%)
T   15.82 (+1.15%)
F   12.02 (-4.53%)
MU   67.98 (-5.18%)
CGC   0.81 (-5.10%)
GE   100.00 (-2.34%)
DIS   87.27 (-0.63%)
AMC   4.43 (-4.32%)
PFE   37.61 (+1.62%)
PYPL   61.47 (-0.93%)
NFLX   393.26 (+0.07%)
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Forecast, Price & News

$2.89
-0.05 (-1.70%)
(As of 11:50 AM ET)
Compare
Today's Range
$2.86
$3.00
50-Day Range
$1.55
$3.30
52-Week Range
$1.09
$4.70
Volume
24,470 shs
Average Volume
341,366 shs
Market Capitalization
$113.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Brainstorm Cell Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
257.1% Upside
$10.00 Price Target
Short Interest
Healthy
9.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.91mentions of Brainstorm Cell Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.61) to ($0.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

320th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

42nd out of 167 stocks


BCLI stock logo

About Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Stock News Headlines

Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
BCLI: Awaiting Adcom Date for NurOwn®…
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
BCLI: Preparing for Adcom for NurOwn®…
See More Headlines
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Company Calendar

Last Earnings
3/30/2023
Today
5/31/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCLI
Fax
N/A
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+240.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.08) per share

Miscellaneous

Free Float
35,350,000
Market Cap
$115.87 million
Optionable
Optionable
Beta
-0.38

Key Executives

  • Chaim Lebovits
    President & Co-Chief Executive Officer
  • Stacy R. Lindborg
    Co-Chief Executive Officer
  • David Setboun
    Chief Operating Officer & Executive Vice President
  • Alla Patlis
    Chief Financial Officer & Controller
  • Yael Gothelf
    Vice President-Scientific & Regulatory Affairs













BCLI Stock - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCLI shares.
View BCLI analyst ratings
or view top-rated stocks.

What is Brainstorm Cell Therapeutics' stock price forecast for 2023?

1 equities research analysts have issued 12 month price objectives for Brainstorm Cell Therapeutics' stock. Their BCLI share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 240.1% from the stock's current price.
View analysts price targets for BCLI
or view top-rated stocks among Wall Street analysts.

How have BCLI shares performed in 2023?

Brainstorm Cell Therapeutics' stock was trading at $1.64 at the start of the year. Since then, BCLI shares have increased by 79.3% and is now trading at $2.94.
View the best growth stocks for 2023 here
.

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 2,870,000 shares, a drop of 9.2% from the April 30th total of 3,160,000 shares. Based on an average trading volume of 359,000 shares, the short-interest ratio is currently 8.0 days. Approximately 9.5% of the company's shares are sold short.
View Brainstorm Cell Therapeutics' Short Interest
.

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our BCLI earnings forecast
.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings data on Thursday, March, 30th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (3.98%), Susquehanna International Group LLP (0.00%), Raymond James & Associates (0.45%), Liberty Wealth Management LLC (0.41%), Group One Trading L.P. (0.00%) and TRU Independence Asset Management 2 LLC (0.12%). Insiders that own company stock include David Setboun, International Holdings Ltd Acc and Sankesh Abbhi.
View institutional ownership trends
.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $2.94.

How much money does Brainstorm Cell Therapeutics make?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a market capitalization of $115.87 million. The biotechnology company earns $-24,280,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.brainstorm-cell.com. The biotechnology company can be reached via phone at (201) 488-0460 or via email at pshah@brainstorm-cell.com.

This page (NASDAQ:BCLI) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -